TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34268888
Drug: Large volume
Normalized name: NEBULIZER,LARGE VOLUME #1770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large volume subcutaneous injection
Study: 34790138
Drug: Betahistine (72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (72 mg/d)
Study: 35835135
Drug: Doxorubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin plus trabectedin (60 mg/m2 doxorubicin and 1.1 mg/m2 trabectedin)
Study: 35835135
Drug: Doxorubicin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin alone (75 mg/m2)
Study: 33749741
Drug: Intravenous 8‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 8‐mg dose of dexamethasone
Study: 33090380
Drug: P‐Ser treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐Ser treatment for 12 months
Study: 35970815
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (n=203)
Study: 35970815
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic treatment (n=360)
Study: 35970815
Drug: Rifaximin treatment
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin treatment (specific numbers not provided)
Study: 35970815
Drug: Long-term antibiotic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antibiotic prophylaxis at discharge (specific numbers not provided)
Study: 32319076
Drug: Levodopa inhalation
Normalized name: levodopa Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa inhalation powder 84 mg
Study: 32247315
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride (BH) spray
Study: 35559243
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of ziprasidone (60–80 mg/d) in combination with sertraline
Study: 35559243
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose of ziprasidone (120–160 mg/d) monotherapy
Study: 35322843
Drug: Cranberry (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry (9 g powder solubilized in water equivalent to 100 g of fresh cranberries, 525 mg total (poly)phenols)
Study: 35322843
Drug: Control (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (9 g powder, no (poly)phenols)
Study: 34567223
Drug: Peppermint essential
Normalized name: Nature's Truth Peppermint Essential Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint essential oil (3 drops inhaled for 7 nights)
Study: 34567223
Drug: Lavender essential
Normalized name: Nature's Truth Lavender Essential Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender essential oil (3 drops inhaled for 7 nights)
Study: 34567223
Drug: Control (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (3 drops of aromatic placebo inhaled for 7 nights)
Study: 34644472
Drug: Cell-culture-derived quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-culture-derived quadrivalent inactivated influenza vaccine (IIV4c)
Study: 34644472
Drug: Meningococcal ACWY
Normalized name: meningococcal ACWY, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal ACWY vaccine (control)
Study: 34131001
Drug: Crossover veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover veliparib monotherapy (300-400 mg twice daily continuous)
Study: 34131001
Drug: Crossover veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover veliparib monotherapy
Study: 32157678
Drug: Individually customized
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually customized tapering plan at discharge combined with telephone counselling one week after discharge
Study: 32157678
Drug: No tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tapering plan or telephone counselling
Study: 38367750
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg vaginal misoprostol
Study: 38367750
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg vaginal misoprostol
Study: 35908869
Drug: PCV13 (13-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 (13-valent pneumococcal vaccine)
Study: 32702912
Drug: Low-intensity pelvic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity pelvic floor muscle training (PFMT) twice a week for 15 minutes per day for 12 weeks
Study: 33350994
Drug: Caffeinated energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated energy dietary supplement (55 mg of caffeine)
Study: 35570329
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone (8 mg)
Study: 34661562
Drug: Smart pill
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smart pill bottle reminder intervention for 4 weeks
Study: 33595885
Drug: Excimer light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excimer light and topical calcipotriol
Study: 32901654
Drug: Silica gel
Normalized name: Silica gel
DrugBank: Silicon dioxide (DB11132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Silica gel desiccator (27.19 °C, 26.19% RH) for drying
Study: 36282407
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS); 18 sessions (twice a week for nine weeks)
Study: 35482651
Drug: Behaviorally based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviorally based weight-loss treatments (BBWLTs)
Study: 32558218
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents after OA
Study: 33143547
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kgBW)
Study: 32046537
Drug: Whole-body hot
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body hot pack thermal therapy (HPTT)
Study: 32046537
Drug: Waon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waon therapy (WT)
Study: 32126990
Drug: Topical regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical regimen
Study: 39046695
Drug: Long-acting muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting muscarinic antagonist (LAMA)
Study: 34537184
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial appendage occlusion (LAAO) using Amplatzer Amulet or Watchman FLX with lifelong aspirin 75 mg daily
Study: 32577745
Drug: Levothyroxine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (starting with 50 μg, adjusted for weight and coronary heart disease)
Study: 38627668
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 0.15 mg/kg
Study: 36071444
Drug: Step-up arm:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-up arm: Intra-articular corticosteroid injection (IACI) in all affected joints for less severe oligoarthritis; IACI and methotrexate for polyarthritis or severe oligoarthritis.
Study: 36071444
Drug: Step-down arm:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down arm: 6-month early combined treatment (methotrexate plus IACI for less severe oligoarthritis; methotrexate plus etanercept for severe oligoarthritis and polyarthritis).
Study: 34309839
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) at 70 L min−1
Study: 32127550
Drug: Ecologic Femi+
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ecologic Femi+ vaginal capsule
Study: 32127550
Drug: Gynophilus LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynophilus LP vaginal tablet
Study: 33430957
Drug: Computer-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based cognitive training intervention using Attentive Rehabilitation of Attention and Memory (ARAM) software, 45 minutes per session, twice a week for 10 sessions.
Study: 35346115
Drug: Psychotherapy (cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (cognitive behavioural therapy)
Study: 33371483
Drug: 2S-Hesperidin 500
Normalized name: hesperidin complex 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2S-Hesperidin 500 mg/day
Study: 33371483
Drug: Placebo (microcellulose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (microcellulose) 500 mg/day
Study: 32971314
Drug: Acute-phase cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute-phase cognitive therapy (CT)
Study: 36195993
Drug: Nitrate treatment
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate treatment
Study: 36264097
Drug: Actovegin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin (1200 mg daily, intravenously for two weeks, followed by oral administration for 10 weeks)
Study: 33038289
Drug: Deutetrabenazine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine 15 mg (fed state)
Study: 33038289
Drug: Deutetrabenazine 7.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine 7.5, 15, and 22.5 mg (repeated dosing)
Study: 33038289
Drug: Deutetrabenazine 6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine 6, 12, 18, and 24 mg (with standard meal)
Study: 33038289
Drug: Deutetrabenazine 18
Normalized name: deutetrabenazine 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine 18 mg (with high-fat meal)
Study: 33038289
Drug: Deutetrabenazine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine (any dose)
Study: 33038289
Drug: Tetrabenazine 25
Normalized name: tetrabenazine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabenazine 25 mg (fasted state)
Study: 33887492
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue sealant (2 ml per 100 cm2 surface area)
Study: 35523943
Drug: Tolcapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (200 mg t.i.d.)
Study: 33148308
Drug: Rescue intervention
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue intervention strategy (RIS) with budesonide/formoterol plus original treatment until AQI < 200
Study: 33148308
Drug: Original treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original treatment (no inhaled medicine, SABA on demand, or budesonide/formoterol 160 μg/4.5 μg/dose, 1–2 dose/time, b.i.d.)
Study: 36098814
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg) administered 1 hour before surgery
Study: 35045567
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate (ALN) 70 mg weekly for 52 weeks
Study: 34029455
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (250 mg every 4 weeks)
Study: 32271183
Drug: FDC IBU/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC IBU/APAP 250/500 mg
Study: 34304913
Drug: IBU 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBU 250 mg
Study: 35965962
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion combined with crystalloid coload
Study: 35965962
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion combined with colloid coload
Study: 33482135
Drug: Ningmitai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningmitai capsule (NMT)
Study: 32157418
Drug: Ruxolitinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib treatment
Study: 33713057
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen at 10mg/kg/dose 8 hourly
Study: 33713057
Drug: Intravenous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac sodium at 1mg/kg/dose 8 hourly
Study: 32683359
Drug: Standard antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotics (penicillin or ampicillin)
Study: 33915251
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2)
Study: 35855841
Drug: TWG tablets
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TWG tablets + acitretin capsules (Group A)
Study: 35855841
Drug: Compound glycyrrhizin
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound glycyrrhizin capsules + acitretin capsules (Group B)
Study: 35855841
Drug: Acitretin capsules
Normalized name: Acitretin Capsules
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin capsules (Group C)
Study: 36470077
Drug: SCTV01C 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTV01C 20 μg
Study: 36470077
Drug: SCTV01C 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTV01C 40 μg
Study: 32199723
Drug: Top concern
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top concern group (control + video addressing the top HPV vaccine concern)
Study: 35500460
Drug: Durvalumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab with concurrent chemoradiotherapy (CCRT) including etoposide and cisplatin, 4 cycles every 3 weeks, followed by durvalumab consolidation therapy every 4 weeks for up to 2 years.
Study: 33592841
Drug: T-MSAT +
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-MSAT + integrative Korean medicine therapy (IKMT)
Study: 32343940
Drug: Uvulopalatopharyngoplasty (UPPP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uvulopalatopharyngoplasty (UPPP) with hyoid suspension (HS)
Study: 32343940
Drug: Barbed reposition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barbed reposition pharyngoplasty (BRP) with hyoid suspension (HS)
Study: 33347474
Drug: Rotavirus vaccine
Normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus vaccine (RV) and pneumococcal conjugate vaccine (PCV)
Study: 34982486
Drug: 1.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/day of EPA/DHA
Study: 33581283
Drug: 20 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Hz rTMS treatment at the dorsolateral prefrontal cortex (DLPFC) for 30 sessions over six weeks (five days per week) with a three-month follow-up.
Study: 33581283
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment group for 30 sessions over six weeks (five days per week) with a three-month follow-up.
Study: 34323584
Drug: Maximum likelihood
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum likelihood (ML)
Study: 35199592
Drug: Olive cream
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive cream
Study: 35301133
Drug: Aspirin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (two common dosages)
Study: 35373017
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg Dulaglutide (DU) weekly
Study: 35373017
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine (IG) daily
Study: 34682669
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy Group (PTG)
Study: 32901323
Drug: Conventional Treatment
Normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Treatment (Group C)
Study: 38525605
Drug: MRA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRA treatment
Study: 34212476
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral (DAA) therapy
Study: 35357350
Drug: Increased anti-infective
Normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased anti-infective treatment
Study: 37454789
Drug: 38% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% silver diamine fluoride (SDF) solution
Study: 36352742
Drug: All experimental
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All experimental treatments (including RSM and FRSM)
Study: 35157830
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg orally twice daily)
Study: 35157830
Drug: Control (enzalutamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (enzalutamide 160 mg orally once daily or abiraterone 1000 mg orally once daily plus prednisone 5 mg orally twice daily)
Study: 36360996
Drug: TaU +
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TaU + MIND (treatment as usual plus mindfulness-based therapy)
Study: 37452281
Drug: TaU (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TaU (treatment as usual)
Study: 34541872
Drug: RG‐TFV rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG‐TFV rectal gel daily
Study: 34541872
Drug: RG‐TFV rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG‐TFV rectal gel before and after receptive anal intercourse (RAI)
Study: 34541872
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three PrEP regimens (RG‐TFV daily, RG‐TFV before and after RAI, and daily oral FTC/TDF)
Study: 34556559
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving four sequential biphasic shocks of 150 J, 200 J, 360 J and 360 J with chest pressure on the last shock.
Study: 33395734
Drug: Treatment Group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Group 2 (n=18) received a booklet, a tailored care plan, and four coaching sessions
Study: 33395734
Drug: Treatment Group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Group 1 (n=7) received an educational booklet
Study: 35050957
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide/oxygen (N2O/O2) 50%-50% equimolar mixture (EMONO)
Study: 32964918
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 21 g (300 mg/kg) for 20 hours
Study: 32745306
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy for 5 days
Study: 32745306
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy for 3 days
Study: 32298202
Drug: CART-19 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: CART-19 (high dose 5 × 10^8)
Study: 32298202
Drug: CART-19 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: CART-19 (low dose 5 × 10^7)
Study: 35144958
Drug: IMPACT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IMPACT intervention (mHealth application, symptom watch, tailored health intervention) for 8 weeks with weekly activities including symptom monitoring, goal setting, and progress monitoring.
Study: 33433041
Drug: NB-UVB phototherapy
Normalized name: Nb
DrugBank: Niobium (DB13031)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB-UVB phototherapy plus 480 mg oral Polypodium leucotomos (PL) twice daily
Study: 34128884
Drug: Pulsed radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed radiofrequency (PRF) at 42°C for 120 seconds plus oral alpha lipoic acid (ALA) 600 mg three times per day for 3 weeks then 600 mg once daily for 2 weeks
Study: 36328157
Drug: Edoxaban (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (once daily for 3 months)
Study: 36328157
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SOC) anticoagulation (low molecular weight heparins or vitamin K antagonists)
Study: 33615173
Drug: CIGB-325 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIGB-325 (2.5 mg/kg/day during 5 consecutive days) plus standard-of-care
Study: 34082177
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg natural oregano essential oil (NOEO)
Study: 34082177
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg synthetic oregano essential oil (SOEO)
Study: 34082177
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg colistin sulfate and 20 mg/kg virginiamycin (antibiotics)
Study: 34082177
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (antibiotic-free)
Study: 32081599
Drug: Memantine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (5 mg/d)
Study: 32081599
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg/d)
Study: 32282773
Drug: Nonaggressive hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonaggressive hydration (Hartmann's solution at 1.5 mL kg h for the first 24 hours and 30 mL kg during the next 24 hours)
Study: 32282773
Drug: Aggressive hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive hydration (bolus of Hartmann's solution 20 mL kg, followed by an infusion of 3 mL kg h for the first 24 hours and then 30 mL kg for the next 24 hours)
Study: 36273180
Drug: Emotionally Focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotionally Focused Therapy (EFT) for couples, 19-21 sessions
Study: 33575950
Drug: IR‐ESO (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR‐ESO (esomeprazole 20 mg and sodium bicarbonate 1100 mg)
Study: 33575950
Drug: ESO (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESO (esomeprazole delayed release tablet 20 mg)
Study: 32006325
Drug: Polyethylene glycolated
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycolated exenatide injection (PB-119) at doses of 2-200 µg